VivoSim Labs, Inc. (NASDAQ: VIVS) announced it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to raise approximately $4 million in gross proceeds. The private placement involves 4,705,883 shares of common stock, or common stock equivalents, and accompanying warrants, priced at a combined $0.85 per share. The warrants are exercisable following shareholder approval and expire five years after their initial exercise date, carrying an exercise price of $0.85 per share. Additionally, the company agreed, subject to shareholder approval, to amend certain existing May 2024 warrants by reducing their exercise price from $9.60 to $0.85 per share.
The offering is expected to close on or about July 17, 2026, subject to customary closing conditions. VivoSim intends to use the net proceeds for working capital and general corporate purposes. The securities were offered in a private placement exempt from Securities Act registration requirements, and the company has agreed to file a resale registration statement with the U.S. Securities and Exchange Commission covering the shares and warrant shares issued in the transaction. For more details, the full press release is available at https://ibn.fm/7Ov0B.
This capital raise comes as VivoSim Labs positions itself in the pharmaceutical and biotechnology services sector, focusing on testing drugs and drug candidates using three-dimensional human tissue models of the liver and intestine. The company offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. VivoSim anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (FDA) Roadmap to refine animal testing requirements in favor of non-animal NAM methods. The company operates from San Diego, CA, and more information can be found on its website at https://vivosim.ai/.
The significance of this private placement lies in the company's ability to secure funding from a healthcare-focused institutional investor, signaling confidence in VivoSim's technology and business model. The amendment of existing warrants from a $9.60 exercise price to $0.85 per share may also indicate a strategic move to align incentives and potentially reduce dilution for existing shareholders. For the industry, the advancement of NAM models could reduce reliance on animal testing, aligning with regulatory trends and ethical considerations. For investors, the private placement provides a glimpse into the company's financial strategy and its commitment to advancing its platform.
